Aurigene signs manufacturing supply agreement
Analysis based on 8 articles · First reported Aug 25, 2026 · Last updated Aug 25, 2026
The agreement provides long-term revenue visibility for Aurigene and Abbott Laboratories, with revenue expected to commence in 2028, potentially boosting future earnings. The deal enhances Aurigene's CDMO/CMO capabilities, which may strengthen its competitive position in the contract manufacturing market.
Abbott Laboratories — Aurigene Pharmaceutical Services, a wholly owned subsidiary of Abbott Laboratories, has entered into a long-term Manufacturing and Supply Agreement (MSA) with an undisclosed global pharmaceutical company. The agreement covers commercial drug-product manufacturing and supply for markets in the United States, Europe, Canada, and emerging markets. The initial portfolio includes over 20 products spanning sterile injectables, biologics, and topicals, to be manufactured at Aurigene's facilities in India. Technology transfer will occur in phases over the next two to three years, with commercial manufacturing and supply expected to follow. At full commercialization, the portfolio is expected to represent an annual volume of approximately 18 million units, largely injectables, with revenue commencing in calendar year 2028. The agreement strengthens Aurigene's CDMO and CMO capabilities and provides long-term revenue visibility. The counterparty's identity remains undisclosed due to confidentiality obligations.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard